The lack of research on health and wellness products is greatly hindering our industry’s growth and reputation. Given the high cost and long timeline of traditional clinical trials, in addition to institutions’ aversion to working with CBD/cannabis companies, we’re missing critical research and objective data on the efficacy and safety of our products. In this session, learn how digital health, big tech and cannabis companies themselves are moving the needle on cannabis research to establish consumer trust and improve access to legitimate and beneficial remedies. Bring questions as we explore the obstacles to cannabis research, why it is critical to propelling our industry forward and how to most effectively transform government policy with rigorous real-world evidence on cannabis and CBD.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.
Andrea Baillo
Open Book Extracts
Julia Bramante
Colorado Department Of Public Health And Environment
Harold Han
Vertosa
Arian Roman
Pivital Holdings